Y Y Wang1, K Wang2, S W Li2, J F Wang3, J Ma2, T Jiang4, J P Dai5. 1. From the Departments of Neurosurgery (Y.Y.W., J.F.W., T.J.) Beijing Neurosurgical Institute (Y.Y.W., T.J., J.P.D.), Capital Medical University, Beijing, China. 2. Neuroradiology (K.W., S.W.L., J.M., J.P.D.), Beijing Tian Tan Hospital. 3. From the Departments of Neurosurgery (Y.Y.W., J.F.W., T.J.). 4. From the Departments of Neurosurgery (Y.Y.W., J.F.W., T.J.) Beijing Neurosurgical Institute (Y.Y.W., T.J., J.P.D.), Capital Medical University, Beijing, China Center for Brain Tumor (T.J.), Beijing Institute for Brain Disorders, Beijing, China. taojiang1964@163.com djpbeijing@hotmail.com. 5. Neuroradiology (K.W., S.W.L., J.M., J.P.D.), Beijing Tian Tan Hospital Beijing Neurosurgical Institute (Y.Y.W., T.J., J.P.D.), Capital Medical University, Beijing, China taojiang1964@163.com djpbeijing@hotmail.com.
Abstract
BACKGROUND AND PURPOSE: It is proposed that isocitrate dehydrogenase 1 (IDH1) mutation predicts the outcome in patients with high-grade glioma. In addition, contrast enhancement on preoperative MR imaging reflects tumor biologic features. Patients with anaplastic glioma with the IDH1 mutation were evaluated by using MR imaging to determine whether tumor enhancement is a prognostic factor and can be used to predict survival. MATERIALS AND METHODS: A cohort of 216 patients with histologically confirmed anaplastic glioma was reviewed retrospectively. Tumor contrast-enhancement patterns were classified on the basis of preoperative T1 contrast MR images. Tumor IDH1 status was examined by using RNA sequencing. We used univariate analysis and the multivariate Cox model to evaluate the prognostic value of the IDH1 mutation and tumor contrast-enhancement pattern for progression-free survival and overall survival. RESULTS: In all 216 patients, IDH1 mutation was associated with longer progression-free survival (P = .004, hazard ratio = 0.439) and overall survival (P = .002, hazard ratio = 0.406). For patients with IDH1 mutant anaplastic glioma, the absence of contrast enhancement was associated with longer progression-free survival (P = .038, hazard ratio = 0.473) and overall survival (P = .043, hazard ratio = 0.436). Furthermore, we were able to stratify the progression-free survival and overall survival of patients with IDH1 mutation by using the tumor contrast-enhancement patterns (P = .022 and 0.029, respectively; log-rank). CONCLUSIONS: Tumor enhancement on postcontrast MR imaging is a valuable prognostic factor for patients with anaplastic glioma and IDH1 mutation. Furthermore, the contrast-enhancement patterns could potentially be used to stratify the survival outcome of such patients.
BACKGROUND AND PURPOSE: It is proposed that isocitrate dehydrogenase 1 (IDH1) mutation predicts the outcome in patients with high-grade glioma. In addition, contrast enhancement on preoperative MR imaging reflects tumor biologic features. Patients with anaplastic glioma with the IDH1 mutation were evaluated by using MR imaging to determine whether tumor enhancement is a prognostic factor and can be used to predict survival. MATERIALS AND METHODS: A cohort of 216 patients with histologically confirmed anaplastic glioma was reviewed retrospectively. Tumor contrast-enhancement patterns were classified on the basis of preoperative T1 contrast MR images. TumorIDH1 status was examined by using RNA sequencing. We used univariate analysis and the multivariate Cox model to evaluate the prognostic value of the IDH1 mutation and tumor contrast-enhancement pattern for progression-free survival and overall survival. RESULTS: In all 216 patients, IDH1 mutation was associated with longer progression-free survival (P = .004, hazard ratio = 0.439) and overall survival (P = .002, hazard ratio = 0.406). For patients with IDH1 mutant anaplastic glioma, the absence of contrast enhancement was associated with longer progression-free survival (P = .038, hazard ratio = 0.473) and overall survival (P = .043, hazard ratio = 0.436). Furthermore, we were able to stratify the progression-free survival and overall survival of patients with IDH1 mutation by using the tumor contrast-enhancement patterns (P = .022 and 0.029, respectively; log-rank). CONCLUSIONS:Tumor enhancement on postcontrast MR imaging is a valuable prognostic factor for patients with anaplastic glioma and IDH1 mutation. Furthermore, the contrast-enhancement patterns could potentially be used to stratify the survival outcome of such patients.
Authors: Elie Matar; Raymond J Cook; Adam R Fowler; Michael T Biggs; Nicholas S Little; Helen R Wheeler; Bruce G Robinson; Kerrie L McDonald Journal: J Clin Neurosci Date: 2010-06-03 Impact factor: 1.961
Authors: Christian Hartmann; Bettina Hentschel; Wolfgang Wick; David Capper; Jörg Felsberg; Matthias Simon; Manfred Westphal; Gabriele Schackert; Richard Meyermann; Torsten Pietsch; Guido Reifenberger; Michael Weller; Markus Loeffler; Andreas von Deimling Journal: Acta Neuropathol Date: 2010-11-19 Impact factor: 17.088
Authors: Kaisorn L Chaichana; Thomas Kosztowski; Ashwini Niranjan; Alessandro Olivi; Jon D Weingart; John Laterra; Henry Brem; Alfredo Quiñones-Hinojosa Journal: J Neurosurg Date: 2010-08 Impact factor: 5.115
Authors: F Laigle-Donadey; N Martin-Duverneuil; J Lejeune; E Crinière; L Capelle; H Duffau; P Cornu; P Broët; M Kujas; K Mokhtari; A Carpentier; M Sanson; K Hoang-Xuan; J Thillet; J Y Delattre Journal: Neurology Date: 2004-12-28 Impact factor: 9.910
Authors: J A Carrillo; A Lai; P L Nghiemphu; H J Kim; H S Phillips; S Kharbanda; P Moftakhar; S Lalaezari; W Yong; B M Ellingson; T F Cloughesy; W B Pope Journal: AJNR Am J Neuroradiol Date: 2012-02-09 Impact factor: 3.825
Authors: Jason Beiko; Dima Suki; Kenneth R Hess; Benjamin D Fox; Vincent Cheung; Matthew Cabral; Nicole Shonka; Mark R Gilbert; Raymond Sawaya; Sujit S Prabhu; Jeffrey Weinberg; Frederick F Lang; Kenneth D Aldape; Erik P Sulman; Ganesh Rao; Ian E McCutcheon; Daniel P Cahill Journal: Neuro Oncol Date: 2013-12-04 Impact factor: 12.300
Authors: Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling Journal: Acta Neuropathol Date: 2009-06-25 Impact factor: 17.088
Authors: Aleksandrs Krigers; Matthias Demetz; Astrid E Grams; Claudius Thomé; Christian F Freyschlag Journal: Acta Neurochir (Wien) Date: 2022-01-11 Impact factor: 2.816
Authors: J Zhou; M V Reddy; B K J Wilson; D A Blair; A Taha; C M Frampton; R A Eiholzer; P Y C Gan; F Ziad; Z Thotathil; S Kirs; N A Hung; J A Royds; T L Slatter Journal: AJNR Am J Neuroradiol Date: 2017-11-30 Impact factor: 3.825